Matthew Brian Hartz, MD, MPH - Medicare Critical Care (intensivists) in Robbinsdale, MN

Matthew Brian Hartz, MD, MPH is a medicare enrolled "Internal Medicine - Pulmonary Disease" physician in Robbinsdale, Minnesota. He went to University Of North Dakota School Of Medicine and graduated in 1999 and has 25 years of diverse experience with area of expertise as Critical Care (intensivists). He is a member of the group practice North Memorial Health Care, Respiratory Consultants Pa and his current practice location is 3366 Oakdale Ave N, Ste 605, Robbinsdale, Minnesota. You can reach out to his office (for appointments etc.) via phone at (763) 520-2940.

Matthew Brian Hartz is licensed to practice in Iowa (license number 33786) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1518948066.

Contact Information

Matthew Brian Hartz, MD, MPH
3366 Oakdale Ave N, Ste 605,
Robbinsdale, MN 55422-5700
(763) 520-2940
(763) 520-2943



Physician's Profile

Full NameMatthew Brian Hartz
GenderMale
SpecialityCritical Care (intensivists)
Experience25 Years
Location3366 Oakdale Ave N, Robbinsdale, Minnesota
Accepts Medicare AssignmentsYes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Matthew Brian Hartz attended and graduated from University Of North Dakota School Of Medicine in 1999
  NPI Data:
  • NPI Number: 1518948066
  • Provider Enumeration Date: 11/10/2005
  • Last Update Date: 04/06/2016
  Medicare PECOS Information:
  • PECOS PAC ID: 2769436237
  • Enrollment ID: I20060921000523

Medical Identifiers

Medical identifiers for Matthew Brian Hartz such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1518948066NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207RP1001XInternal Medicine - Pulmonary Disease 33786 (Iowa)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
North Memorial HealthRobbinsdale, MNHospital
Maple Grove HospitalMaple grove, MNHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
North Memorial Health Care0042123028483
Respiratory Consultants Pa620473685317

News Archive

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

Hunters' lead ammunition finds way into scavenger birds leading to blindness, seizures and death

Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.

Read more Medical News

› Verified 2 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Matthew Brian Hartz allows following entities to bill medicare on his behalf.
Entity NameRespiratory Consultants Pa
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1356439277
PECOS PAC ID: 6204736853
Enrollment ID: O20040112000044

News Archive

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

Hunters' lead ammunition finds way into scavenger birds leading to blindness, seizures and death

Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.

Read more Medical News

› Verified 2 days ago

Entity NameNorth Memorial Health Care
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1851344907
PECOS PAC ID: 0042123028
Enrollment ID: O20040122000470

News Archive

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

Hunters' lead ammunition finds way into scavenger birds leading to blindness, seizures and death

Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.

Read more Medical News

› Verified 2 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Matthew Brian Hartz is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Matthew Brian Hartz, MD, MPH
3366 Oakdale Ave N, Ste 605,
Robbinsdale, MN 55422-5700

Ph: (763) 520-2940
Matthew Brian Hartz, MD, MPH
3366 Oakdale Ave N, Ste 605,
Robbinsdale, MN 55422-5700

Ph: (763) 520-2940

News Archive

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

Hunters' lead ammunition finds way into scavenger birds leading to blindness, seizures and death

Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.

Read more News

› Verified 2 days ago


Internal Medicine Doctors in Robbinsdale, MN

Dr. Alok Maheshwari, MD
Pulmonary Disease
Medicare: Accepting Medicare Assignments
Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422
Phone: 763-581-5400    Fax: 763-581-5401
Ethan Michael Fruechte, M.D.
Pulmonary Disease
Medicare: Accepting Medicare Assignments
Practice Location: 3300 Oakdale Ave N, Suite 200, Robbinsdale, MN 55422
Phone: 763-581-5400    Fax: 763-520-2099
Matthew Nolan, MD
Pulmonary Disease
Medicare: Accepting Medicare Assignments
Practice Location: 3366 Oakdale Ave N Ste 401, Robbinsdale, MN 55422
Phone: 763-520-2940    
Jerrold Martin Stempel, MD
Pulmonary Disease
Medicare: Not Enrolled in Medicare
Practice Location: 3366 Oakdale Ave N, Suite 315, Robbinsdale, MN 55422
Phone: 763-520-7900    Fax: 763-520-7989
Chike Uchenna Anthony Obi,
Pulmonary Disease
Medicare: Accepting Medicare Assignments
Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422
Phone: 763-581-5400    Fax: 763-581-5401
Dr. John Manion, M.D.
Pulmonary Disease
Medicare: Not Enrolled in Medicare
Practice Location: 3435 West Broadway, Suite 1065, Robbinsdale, MN 55422
Phone: 763-520-1137    Fax: 763-520-1976
Andrew Joob, M.D.
Pulmonary Disease
Medicare: Accepting Medicare Assignments
Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422
Phone: 763-520-5200    

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.